DNAnexus
$50.2M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
DNAnexus is currently valued at N/A as of December 20, 2024. The company has raised a total of $666.0M in funding.
Investment Perspective
DNAnexus's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is DNAnexus Worth in 2025?
As of 2025, DNAnexus is valued at N/A, based on the company's Debt - General funding round in December 20, 2024. This valuation positions DNAnexus as one of the leading private companies in the sector.
DNAnexus Valuation History
DNAnexus's funding history demonstrates steady growth and investor confidence.
How DNAnexus Valuation is Determined
Private company valuations like DNAnexus's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
DNAnexus Valuation FAQs
Is DNAnexus profitable?
DNAnexus has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does DNAnexus's valuation compare to competitors?
DNAnexus is valued at N/A, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will DNAnexus IPO?
DNAnexus has not announced plans for an initial public offering. Until an IPO, investors can access DNAnexus shares through secondary market platforms.